(C) | 1. |
¹L¥h¥¼´¿±µ¨üheparinª`®g¹L¤§¯f¤H¡Aª`®gheparin«á¤Þµo¦å¤pªO§C¤U(Heparin induced thrombocytopenia)³Ì±`¥X²{ªº®É¶¡¬°heparinª`®g«á
|
A. | 1¤Ñ¤º |
B. | 1¦Ü3¤Ñ |
C. | 5¦Ü10¤Ñ |
D. | 14¦Ü28¤Ñ |
E. | 1Ó¤ë«á |
|
(C) | 2. |
¤U¦C¦³ÃöTRALI(transfusion-related acute lung injury)ªº±Ôz¦óªÌ¦³»~¡H
|
A. | ¿éª`¥ô¦ó¦å²G¦¨¤À³£¦³¥i¯àµo¥Í |
B. | ¤@¯ë¦b¿é¦å¤¤©Î¿é¦å«á6¤p®É¤ºµo¥Í |
C. | µo¥Íªºì¦]¥i¯à»P¨ü¦åªÌÅ餺¦³§Ü®½¦åªÌ¥Õ¦å²yªº§ÜÅ馳Ãö |
D. | ¯f¤Hªº¯Ý³¡X¥ú·|¥X²{¨âÃäªÍ¸ªº®û¼í |
E. | ¥Ø«e¨ÃµL©ú½TÃÒ¾ÚÅã¥ÜÃþ©T¾JªvÀø¦³®Ä |
|
(E) | 3. |
¤@¦ì63·³¨k©Ê¦b°·±dÀˬd®É°¸µMµo²{¦å¤pªO¼Æ¬°732,000/uL¡A¦å¬õ¯À¤Î¥Õ¦å²yµL²§±`¡F¨ÅéÀˬd(physical examination)¨ÃµL¯S®íµo²{¡A°ò¦]ÀË´ú¥¼µo²{¦³JAK2¬ðÅÜ¡C¤U¦C¦óºØÀˬdµ²ªG¹ïìµo©Ê¦å¤pªO¼W¥Í¯gªº¶EÂ_³Ì¦³À°§U¡H
|
A. | °©ÅèÅK¬V¦â¥i¬Ý¨ìring sideroblasts |
B. | ¶O«°¬V¦âÅ鶧©Ê |
C. | PDGFRA°ò¦]¬ðÅÜ |
D. | EGFR°ò¦]¬ðÅÜ |
E. | CALR°ò¦]¬ðÅÜ |
|
(D) | 4. |
¤@¦ì¯f¤H¦b©â¦åÀˬd¤¤µo²{PT¬°16.3"(¥¿±`9.8~11.5")¡AINR 1.52¡APTT¬°54.3"(¥¿±`25.6~32.6")¡C¯f¤H³Ì¤£¥i¯à¦³¥H¤U¦óºØª¬ªp¡H
|
A. | Warfarin treatment |
B. | Rivaroxaban treatment |
C. | Aspirin treatment |
D. | Factor XII deficiency |
E. | Liver disease |
|
(A) | 5. |
¤@¦ì52·³¯f¤H©â¦åÀˬdµo²{¥Õ¦å²y¼Æ¬°25,500/uL¡A²O¤Ú²ÓM¦û78%¡A©PÃä¦å²G©Ù¤ù¦p¹Ï©Ò¥Ü¡A¬y¤ó²ÓM»öÅã¥Ü³o¨Ç²O¤Ú²ÓMªí²{CD19¡ACD20¡ACD5¡ACD23¡A¤Î£e-»´Ãì¡A¦ýµLCD3¡ACD10¤Î£f-»´Ãìªí²{¡A¦¹¯f¤H³Ì¥i¯à±o¤F¤°»ò¯f¡H
|
A. | Chronic lymphocytic leukemia |
B. | Large granular lymphocyte leukemia |
C. | Reactive lymphocytosis |
D. | Acute lymphoblastic leukemia |
E. | Follicular lymphoma |
|
(E) | 6. |
¤@¦ì17·³¨k©Ê¯f¤H¦]µo¿N¦í°|¡A¦å²GÀˬdÅã¥Ü¬õ¦å²y2,350,000/uL¡A¥Õ¦å²y1,050/uL¡A¨ä¤¤segmented forms 10%¡Abands 2%¡Alymphocytes 82%¡Amonocytes 6%¡A¦å¤pªO16,400/uL¡Aºôª¬¬õ¦å²y1%¡F¨Ï¥Î§Ü¥Í¯À«á¡AÅé·Å¦^´_¥¿±`¡C°©ÅèÀˬdÅã¥Ü¬°¦A¥Í¤£¨}©Ê³h¦å¡A¤U¤@¨B³Ì¾A·íªºªvÀø¬°¦ó¡H
|
A. | Antithymocyte globulin |
B. | Cyclosporine |
C. | Antithymocyte globulin¤Îcyclosporine |
D. | Anabolic hormone |
E. | Allogeneic hematopoietic stem cell transplantation from a HLA-matched sibling donor |
|
(C) | 7. |
¤@¦hµo©Ê°©Åè½F±wªÌ¡A¦å²GÀˬdÅã¥Ü¦å¬õ¯À10.5 gm/dL¡A¥Õ³J¥Õ3.6 gm/dL¡A²y³J¥Õ5.1 gm/dL¡ACr 1.1 mg/dL¡A£]2-microglobulin 4.1 mg/L¡A¦¹¯f¤H¦b°ê»Ú¤À´Á¨t²Î(International Staging System)¤§´Á§O¬°¡H
|
A. | 0 |
B. | I |
C. | II |
D. | III |
E. | IV |
|
(E) | 8. |
¤@¦ì47·³¨k©Ê·s¶EÂ_¥X¦³ºC©Ê°©Åè©Ê¥Õ¦å¯f¡A¤U¦C¦³Ãö¦¹¯f¤Hªº±Ôz¦óªÌ¬O¥¿½Tªº¡H(À³¿ï¥X©Ò¦³¥¿½Tµª®×)
(1)¦³¬V¦âÅ鲧±`t(9;22)
(2)¦³²§±`¤§¿Ä¦X°ò¦]BCR-ABL
(3)³Ì¾A·íªºªvÀø¬°¹TÓi»Ä¿EúC§í¨î¾¯(tyrosine kinase inhibitor)
|
A. | (1) |
B. | (2) |
C. | (1)+(2) |
D. | (1)+(3) |
E. | (1)+(2)+(3) |
|
(B) | 9. |
¤@¦ì58·³¤k©Ê¡A¦]ÀV³¡²O¤Úµ²¸~¤j±µ¨ü¤Á¤ùÀˬd¡A¯f²zªì¨B³ø§i¬°ºÃ¦üÂoªw«¬²O¤Ú½F(follicular lymphoma)¡C¤U¦C¦óºØÀˬdµ²ªG¥i¥HÀ°¦£¶EÂ_Âoªw«¬²O¤Ú½F¡H(À³¿ï¥X©Ò¦³¥¿½Tµª®×)
(1) t(14;18)
(2) BCL-2²§±`ªí²{
(3) CD5²ÓMªí±§Ü춧©Ê
|
A. | (1) |
B. | (1)+(2) |
C. | (1)+(3) |
D. | (2)+(3) |
E. | (1)+(2)+(3) |
|
(E) | 10. |
¤U¦C¦óºØª¬ªp¦³¥i¯à³y¦¨¥þ¦å²y´î¤Ö¡H(À³¿ï¥X©Ò¦³¥¿½Tµª®×)
(1) Vit B12 deficiency
(2) Myelodysplastic syndrome
(3) Liver cirrhosis
(4) Autoimmune disease
|
A. | (4) |
B. | (2)+(4) |
C. | (2)+(3) |
D. | (2)+(3)+(4) |
E. | (1)+(2)+(3)+(4) |
|